Editas Medicine Logo

Editas Medicine

🇺🇸
EDIT
US28106W1036

Editas Medicine is a leading US-based biotechnology company specializing in the development of innovative gene therapies. Utilizing CRISPR gene-editing technology, the company researches transformative treatment methods for serious genetic diseases to improve patient outcomes through precision medicine.

Next Quarterly Earnings

Monday, November 9, 2026
CW 46
After-Hours
In 74 days

After-hours — typically from around 10:00 p.m. German time (after the US close at 4:00 p.m. New York time).

Quiet period starts on October 12, 2026

Stock Price

Frequently asked questions

When will Editas Medicine report its next quarterly earnings?

Editas Medicine is scheduled to report its next quarterly earnings on 11/09/2026. After-hours — typically from around 10:00 p.m. German time (after the US close at 4:00 p.m. New York time).

When did Editas Medicine last report quarterly earnings?

Editas Medicine last reported quarterly earnings on 8/5/2026 (Q2 2026). Earnings per share (EPS) came in at -0.15 USD.

How often has Editas Medicine beaten expectations?

Editas Medicine has beaten analyst EPS estimates in 5 of its last 5 evaluated quarters (beat rate: 100%).

How do I add the Editas Medicine earnings dates to my calendar?

Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.

All Dates

Q3 2026
Estimate:-$0.20
Actual:
Q2 2026
Beat
Estimate:-$0.27
Actual:-$0.15
Difference:+$0.12
Q1 2026
Beat
Estimate:-$0.26
Actual:-$0.26
Difference:+$0.00
Price reaction (1 day):+1.3 %
Price reaction (7 days):-2.3 %
Q4 2025
Beat
Estimate:-$0.23
Actual:-$0.06
Difference:+$0.17
Price reaction (1 day):+16.0 %
Price reaction (7 days):+27.0 %
Q2 2025
Beat
Estimate:-$0.38
Actual:-$0.28
Difference:+$0.10
Q1 2025
Beat
Estimate:-$0.38
Actual:-$0.32
Difference:+$0.06

Earnings statistics

Estimates vs. results

5/5
Quarters above estimates
100%
Beat rate
+24%
Avg. EPS surprise

Basis: 5 quarters with an analyst estimate and reported EPS.

Past price reactions are not a reliable indicator of future performance.

Company Information

Name
Editas Medicine
Ticker Symbol
EDIT
ISIN
US28106W1036
Country
🇺🇸
USA
Sector